当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant.

Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant.

Abstract：

:This prospective study assessed the endometrial effects of fulvestrant, a pure estrogen-receptor antagonist, in postmenopausal women with breast cancer. This single-center study enrolled postmenopausal patients who had an intact uterus at baseline with progressive metastatic breast cancer on tamoxifen followed by an oral aromatase inhibitor (AI). Fulvestrant (250 mg) was administered every 28 +/- 3 days via IM injection. Transvaginal ultrasonography (TVUS) was performed at baseline and after 3 months of therapy. Primary and secondary endpoints were changes from baseline in double endometrial thickness (DET) and uterine volume (UV), respectively. No interventions were performed on any asymptomatic uterine abnormalities that were detected at baseline. In total, 32 women were enrolled. Five patients had no repeat TVUS because of early progression before 3 months, leaving 27 evaluable patients for final analysis. After 3 months therapy, mean DET had significantly decreased by 23.08% (P = 0.010). Mean UV also decreased by 10.88%, although this change was not significant (P = 0.119). After 3 months of therapy, none reported vaginal bleeding, there were no changes noted in most of the uterine pathologies present at baseline and no new uterine abnormalities were detected. We observed that 3 months of fulvestrant treatment resulted in a significant decrease in endometrial growth and a non-significant decrease in UV in postmenopausal women with metastatic breast cancer previously exposed to tamoxifen and AIs. Furthermore, no new uterine pathologies were detected, indicating that fulvestrant behaves as a pure antiestrogen at the uterine level.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Morales L,Neven P,Timmerman D,Wildiers H,Konstantinovic ML,Christiaens MR,Tan PN,Paridaens R

doi

10.1007/s10549-008-0248-2

subject

Has Abstract

pub_date

2009-09-01 00:00:00

pages

77-81

issue

1

eissn

0167-6806

issn

1573-7217

journal_volume

117

pub_type

临床试验,杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Is bioimpedance spectroscopy a useful tool for objectively assessing lymphovenous bypass surgical outcomes in breast cancer-related lymphedema?

    abstract：PURPOSE:We sought to determine if bioimpedance spectroscopy (BIS) measurements can accurately assess changes in breast cancer-related lymphedema (BCRL) in patients undergoing lymphovenous bypass (LVB). METHODS:Patients undergoing LVB for BCRL refractory to conservative treatment from 1/2015 to 12/2018 were identified ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-020-06059-6

    authors： Sutherland A,Wagner JL,Korentager S,Butterworth J,Amin AL,Balanoff CR,Hangge A,Larson KE

    更新日期：2021-01-04 00:00:00

  • Introduction of hsa-miR-512-3p as a new regulator of HER2 signaling pathway in breast cancer.

    abstract：PURPOSE:Dysregulation of HER2 signaling pathway in breast cancer is well documented. Our bioinformatics analysis predicted hsa-miR-512-3p (miR-512-3p) as a bona fide regulator of HER2 as well as HER3, PIK3R2, and AKT1 genes. Then, we intended to examine the effect of miR-512-3p on the predicted target genes that are in...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05937-3

    authors： Mohamadzade Z,Mahjoubi F,Soltani BM

    更新日期：2021-01-01 00:00:00

  • Psychosocial and physical outcomes of primary breast cancer therapy: mastectomy vs excisional biopsy and irradiation.

    abstract：:Thirty-eight patients treated for primary breast cancer as part of a prospective randomized clinical trial were questioned retrospectively as to their psychosocial adaptation to treatment. Twenty patients had received mastectomy and eighteen had received excisional biopsy plus radiation of the intact breast. Aside fro...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF01807591

    authors： Schain W,Edwards BK,Gorrell CR,de Moss EV,Lippman ME,Gerber LH,Lichter AS

    更新日期：1983-01-01 00:00:00

  • Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women.

    abstract：INTRODUCTION:The incidence of breast cancer varies among women living in the Southwestern part of the US. We evaluate how body size influences breast cancer risk among these women. METHODS:Cases (n = 2,325) diagnosed with breast cancer between October 1, 1999 and May 2004 residing in Arizona, Colorado, New Mexico, or ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9292-y

    authors： Slattery ML,Sweeney C,Edwards S,Herrick J,Baumgartner K,Wolff R,Murtaugh M,Baumgartner R,Giuliano A,Byers T

    更新日期：2007-03-01 00:00:00

  • Cultured cell lines from human breast cancer biopsies and xenografts.

    abstract：:Eighty-five breast cancer specimens were processed as part of a program in tumor acquisition, propagation, and preservation for biotherapy. Nine long-term culture cell lines were developed. Four cell lines were from solid tumor metastases, two lines were from pleural fluid specimens, and three were from xenograft tumo...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01806292

    authors： Lewko WM,Vaghmar R,Hubbard D,Moore M,He YJ,Chang L,Husseini S,Wallwork K,Thurman GB,Oldham RK

    更新日期：1990-12-01 00:00:00

  • Predictive value of lymphoscintigraphy in patients with breast cancer-related lymphedema undergoing complex decongestive therapy.

    abstract：PURPOSE:We evaluated the prognostic value of lymphoscintigraphy after complex decongestive therapy (CDT) in breast cancer-related secondary lymphedema. METHODS:Prior to CDT, 80 patients with breast cancer-related lymphedema underwent a 99mTc tin-colloid lymphoscintigram. We investigated the uptake patterns of axillary...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-5041-2

    authors： Kim YH,Hwang JH,Bae JH,Choi JY

    更新日期：2019-02-01 00:00:00

  • The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data.

    abstract：BACKGROUND:Several randomized controlled trials have confirmed the usefulness of trastuzumab as an adjuvant therapy for HER2-overexpressed breast cancer patients; however, the costs for 1-year treatment are high. Therefore, we performed an economic analysis regarding the efficient distribution of medical resources. ME...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9679-4

    authors： Shiroiwa T,Fukuda T,Shimozuma K,Ohashi Y,Tsutani K

    更新日期：2008-06-01 00:00:00

  • Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer.

    abstract：:Paclitaxel and vinorelbine are among the most active new agents in metastatic breast cancer. Both in vitro and in vivo studies have shown that the combined administration of these two microtubule-targeting agents is feasible and worthwhile. Based on the promising preclinical data, patients with metastatic breast cance...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1023/a:1005848921895

    authors： Tortoriello A,Facchini G,Caponigro F,Santangelo M,Benassai G,Persico G,Citarella A,Carola M,Marzano N,Iaffaioli RV

    更新日期：1998-01-01 00:00:00

  • Assessing interactions between the associations of fibroblast growth factor receptor 2 common genetic variants and hormone receptor status with breast cancer risk.

    abstract：:Fibroblast growth factor receptor 2 (FGFR2) is a member of a receptor tyrosine kinase gene superfamily, involved in cell growth, invasiveness, motility, and angiogenesis, which has attracted considerable attention as a candidate gene for breast cancer (BC) since it was first identified through genome-wide association ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析

    doi：10.1007/s10549-012-2343-7

    authors： Wang H,Yang Z,Zhang H

    更新日期：2013-01-01 00:00:00

  • G:C > A:T mutations and potential epigenetic regulation of p53 in breast cancer.

    abstract：:Analysis of germline p53 mutations in breast cancer reveals that the Li-Fraumeni and Li-Fraumeni-like syndromes are mostly related to the loss of initiation codon 133 of regulatory TP53 isoforms (Delta133p53). In eight codons of exons 5-8 (including 133), mutations are frequent in Li-Fraumeni-related, but scarce in sp...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9514-y

    authors： Kouidou S,Malousi A,Kyventidis A,Fragou A,Maglaveras N

    更新日期：2007-12-01 00:00:00

  • The pathology of breast cancer in Japanese women compared to other ethnic groups: a review.

    abstract：:Review of comparative pathology studies of breast cancer among Japanese women and other ethnic groups reveals consistent differences in tumor morphology and host response. Japanese women show lower rates of breast cancer than Caucasian women, a difference that is accounted for by increased rates of this cancer in post...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF02633531

    authors： Stemmermann GN

    更新日期：1991-05-01 00:00:00

  • Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients.

    abstract：:MicroRNAs play a role in breast cancer development and progression by post-transcriptional repression of the expression of important genes, such as the tumor suppressor gene phosphatase and tensin homolog (PTEN). The focus of the current study was to examine the diagnostic potential of circulating cell-free microRNAs ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-1988-6

    authors： Schwarzenbach H,Milde-Langosch K,Steinbach B,Müller V,Pantel K

    更新日期：2012-08-01 00:00:00

  • The 17q23 amplicon and breast cancer.

    abstract：:A novel region of amplification in breast tumors was recently identified on chromosome 17q23. Extensive mapping of the amplicon by Southern blotting and fluorescence in situ hybridization (FISH) in breast cancer cell lines determined that the amplicon can be up to 4 Mbp in size and may contain 50 genes. Copy number an...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1023/a:1023081624133

    authors： Sinclair CS,Rowley M,Naderi A,Couch FJ

    更新日期：2003-04-01 00:00:00

  • Women with breast cancer report substantially more disease- and treatment-related side or late effects than registered by clinical oncologists: a cross-sectional study of a standard follow-up program in an oncological department.

    abstract：BACKGROUND:Follow-up after breast cancer treatment is standard due to the risk of development of new primary cancers and recurrent disease. The aim of the present study was to evaluate a standard follow-up program in an oncological department by assessing: (1) Symptoms or signs of new primary cancer or recurrent diseas...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4301-x

    authors： Ellegaard MB,Grau C,Zachariae R,Jensen AB

    更新日期：2017-08-01 00:00:00

  • The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.

    abstract：INTRODUCTION:Long-term endocrine therapy for breast cancer may have clinical implications as drugs that potentially alter the lipid profile may increase the risk of developing cardiovascular disease. In this study, a companion sub-protocol to the TEAM (Tamoxifen and Exemestane Adjuvant Multicenter) International trial,...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-005-3783-0

    authors： Markopoulos C,Polychronis A,Zobolas V,Xepapadakis G,Papadiamantis J,Koukouras D,Lappas H,Gogas H

    更新日期：2005-09-01 00:00:00

  • Progesterone receptors and human breast cancer.

    abstract：:Estrogen receptor protein is known to be an important prognostic factor for patients with breast cancer. The presence of estrogen receptor correlates with response to endocrine therapy in patients with metastatic disease and is associated with prolonged disease-free and overall survival in patients with primary diseas...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF01803558

    authors： Clark GM,McGuire WL

    更新日期：1983-01-01 00:00:00

  • Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer.

    abstract：BACKGROUND:We recently showed PAM50 gene expression data can be represented by five quantitative, orthogonal, multi-gene breast tumor traits. These novel tumor 'dimensions' were superior to categorical intrinsic subtypes for clustering in high-risk breast cancer pedigrees, indicating potential to represent underlying g...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-05097-5

    authors： Camp NJ,Madsen MJ,Herranz J,Rodríguez-Lescure Á,Ruiz A,Martín M,Bernard PS

    更新日期：2019-05-01 00:00:00

  • Breast cancer expresses functional NMDA receptors.

    abstract：:We demonstrate here that functional NMDAR1 and NMDAR2 receptors are expressed by Mcf-7 and SKBR3 breast cancer cell lines, and possibly by most or all high-grade breast tumors, and that these receptors are important for the growth of human breast cancer xenografts in mice. RT-PCR demonstrated mRNA for both NMDAR1 and ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0556-1

    authors： North WG,Gao G,Memoli VA,Pang RH,Lynch L

    更新日期：2010-07-01 00:00:00

  • NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup.

    abstract：:To explain a bimodal relapse hazard among early stage breast cancer patients treated by mastectomy we postulated that relapses within 4 years of surgery resulted from something that happened at about the time of surgery to provoke sudden exits from dormant phases to active growth. Relapses at 10 months appeared to be ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2094-5

    authors： Retsky M,Rogers R,Demicheli R,Hrushesky WJ,Gukas I,Vaidya JS,Baum M,Forget P,Dekock M,Pachmann K

    更新日期：2012-07-01 00:00:00

  • Long-term dysregulation of circadian and 17-beta estradiol-induced LH, prolactin and corticosterone secretion after dimethylbenz (a) anthracene administration in the Sprague-Dawley female rat.

    abstract：:A single intragastric administration of 7,12-dimethylbenz (a) anthracene (DMBA) has been shown, when given at 55-60 days of age, to induce mammary tumors in young cycling female Sprague-Dawley rats. The appearance of the tumors is preceded by a series of neuroendocrine disturbances of the hypothalamo-pituitary-gonadal...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-005-0270-6

    authors： Yon de Jonage-Canonico MB,Lenoir V,Scholler R,Kerdelhué B

    更新日期：2005-07-01 00:00:00

  • Intra-operative ultrasound versus wire-guided localization in the surgical management of non-palpable breast cancers: systematic review and meta-analysis.

    abstract：INTRODUCTION:The current standard of treatment for non-palpable breast cancers is wire-guided localization (WGL). WGL has its drawbacks and alternatives such as radio-guided surgery (RGL) and intra-operative ultrasound (IOUS) have been developed. The clinical effectiveness of all forms of RGL has been assessed against ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s10549-013-2639-2

    authors： Ahmed M,Douek M

    更新日期：2013-08-01 00:00:00

  • Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer.

    abstract：PURPOSE:Platinum plays an important role in the treatment of triple-negative breast cancer (TNBC) in neoadjuvant and metastatic settings. However, its role in an adjuvant setting remains unclear. METHODS:In this non-inferior randomized phase 2 trial, we randomly assigned 308 chemotherapy-naive patients with histologic...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-020-05648-9

    authors： Du F,Wang W,Wang Y,Li M,Zhu A,Wang J,Cai R,Ma F,Fan Y,Li Q,Zhang P,Todorovic V,Yuan P,Xu B

    更新日期：2020-07-01 00:00:00

  • Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients.

    abstract：PURPOSE:The RAS family comprises three proto-oncogenes (H-RAS, K-RAS, and N-RAS) and is among the most widely studied of oncogenes. The present study aimed at investigating the clinical relevance of mRNA levels of the three isoforms in a large group of breast cancer patients with a long-term follow-up. METHODS:198 pre...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05474-8

    authors： Banys-Paluchowski M,Milde-Langosch K,Fehm T,Witzel I,Oliveira-Ferrer L,Schmalfeldt B,Müller V

    更新日期：2020-01-01 00:00:00

  • Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer.

    abstract：:Ductal carcinoma in situ (intraductal carcinoma) of the breast is a commonly recognized and curable clinical entity. Patients with intraductal carcinoma are at risk to develop invasive breast cancer presumably due to a transition from the noninvasive to the invasive phase of growth. Primary breast malignancies commonl...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00689717

    authors： Iglehart JD,Kerns BJ,Huper G,Marks JR

    更新日期：1995-06-01 00:00:00

  • Protein S and protein C level changes with adjuvant tamoxifen therapy in postmenopausal women.

    abstract：:Tamoxifen citrate is a synthetic antiestrogen that provides survival benefit when given as adjuvant treatment in postmenopausal women with breast cancer. Venous thrombophlebitis may complicate tamoxifen treatment at a rate of approximately one per 800 treatment-years. To explore the possible procoagulant effects assoc...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF00665973

    authors： Mamby CC,Love RR,Feyzi JM

    更新日期：1994-01-01 00:00:00

  • Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status.

    abstract：:The clinicopathologic, mammographic, and sonographic findings in patients with pure ductal carcinoma in situ (DCIS) were assessed by estrogen receptor (ER) expression. After institutional review board approval, patients with pure DCIS evaluated from January 1996 to July 2009 with known ER status and available imaging ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2598-7

    authors： Rauch GM,Kuerer HM,Scoggins ME,Fox PS,Benveniste AP,Park YM,Lari SA,Hobbs BP,Adrada BE,Krishnamurthy S,Yang WT

    更新日期：2013-06-01 00:00:00

  • Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.

    abstract：:The article Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial, written by Ulrike Nitz, Oleg Gluz, Matthias Christgen, Ronald E. Kates, Michael Clemens, Wolfr...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,已发布勘误

    doi：10.1007/s10549-018-05105-8

    authors： Nitz U,Gluz O,Christgen M,Kates RE,Clemens M,Malter W,Nuding B,Aktas B,Kuemmel S,Reimer T,Stefek A,Lorenz-Salehi F,Krabisch P,Just M,Augustin D,Liedtke C,Chao C,Shak S,Wuerstlein R,Kreipe HH,Harbeck N

    更新日期：2019-05-01 00:00:00

  • Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.

    abstract：PURPOSE:The role of sentinel lymph node biopsy (SLNB) in breast cancer patients who undergo neoadjuvant chemotherapy (NAC) remains controversial. This study aims to investigate if axillary lymph node dissection (ALND) could be safely omitted after a negative SLNB in cN1/2 patients who become cN0 after NAC. METHODS:We ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-06011-8

    authors： Damin AP,Zancan M,Melo MP,Biazus JV

    更新日期：2020-11-09 00:00:00

  • Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.

    abstract：BACKGROUND:TOP2A gene encodes topoisomerase II alpha, the direct molecular target of anthracyclines. This gene is frequently coamplified with HER2. The aims of this study were to analyse the pattern of TOP2A amplification and protein expression in relation to the molecular subgroups of breast cancers; and to define the...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9492-5

    authors： Arriola E,Rodriguez-Pinilla SM,Lambros MB,Jones RL,James M,Savage K,Smith IE,Dowsett M,Reis-Filho JS

    更新日期：2007-12-01 00:00:00

  • A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer.

    abstract：PURPOSE:To update and expand on data related to treatment, resource utilization, and costs by cancer stage in Canadian patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC). METHODS:We analyzed data for adult women diagnosed with invasive HR+/HER2- B...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05960-4

    authors： Brezden-Masley C,Fathers KE,Coombes ME,Pourmirza B,Xue C,Jerzak KJ

    更新日期：2020-10-16 00:00:00